C-erbB2 and Topoisomerase IIalpha Protein Expression Independently Predict Poor Survival in Primary Human Breast Cancer: a Retrospective Study

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2005 Jul 1

PMID 15987433

Citations 24

Authors

Peter Fritz

Cristina M Cabrera

Jurgen Dippon

Andreas Gerteis

Wolfgang Simon

Walter E Aulitzky

Heiko van der Kuip

Affiliations

Soon will be listed here.

Abstract

Introduction: c-erbB2 (also known as HER-2/neu) and topoisomerase IIalpha are frequently overexpressed in breast cancer. The aim of the study was to analyze retrospectively whether the expression of c-erbB2 and topoisomerase IIalpha protein influences the long-term outcome of patients with primary breast cancer.

Methods: In this study c-erbB2 and topoisomerase IIalpha protein were evaluated by immunohistochemistry in formalin-fixed paraffin-embedded tissue from 225 samples of primary breast cancer, obtained between 1986 and 1998. The prognostic value of these markers was analyzed.

Results: Of 225 primary breast tumor samples, 78 (34.7%) showed overexpression of either c-erbB2 (9.8%) or topoisomerase IIalpha protein (24.9%), whereas in 21 tumors (9.3%) both proteins were found to be overexpressed. Patients lacking both c-erbB2 and topoisomerase IIalpha overexpression had the best long-term survival. Overexpression of either c-erbB2 or topoisomerase IIalpha was associated with shortened survival, whereas patients overexpressing both c-erbB2 and topoisomerase IIalpha showed the worst disease outcome (P < 0.0001). Treatment with anthracyclines was not capable of reversing the negative prognostic impact of topoisomerase IIalpha or c-erbB2 overexpression.

Conclusion: The results of this exploratory study suggest that protein expression of c-erbB2 and topoisomerase IIalpha in primary breast cancer tissues are independent prognostic factors and are not exclusively predictive factors for anthracycline response in patients with primary breast cancer.

Citing Articles

TOP2A deficit-induced abnormal decidualization leads to recurrent implantation failure via the NF-κB signaling pathway.

Fu H, Tan W, Chen Z, Ye Z, Duan Y, Huang J Reprod Biol Endocrinol. 2022; 20(1):142.

PMID: 36138481 PMC: 9494868. DOI: 10.1186/s12958-022-01013-1.

Bioinformatics analysis shows that TOP2A functions as a key candidate gene in the progression of cervical cancer.

Zhao Q, Li H, Zhu L, Hu S, Xi X, Liu Y Biomed Rep. 2020; 13(4):21.

PMID: 32765860 PMC: 7403841. DOI: 10.3892/br.2020.1328.

Clinical significance of topoisomerase-II expression in patients with advanced non-small cell lung cancer treated with amrubicin.

Sakurai R, Kaira K, Miura Y, Sunaga N, Saito R, Oyama T Thorac Cancer. 2020; 11(2):426-435.

PMID: 31901017 PMC: 6997014. DOI: 10.1111/1759-7714.13289.

Ultrasound microbubble-mediated CRISPR/Cas9 knockout of C-erbB-2 in HEC-1A cells.

Cai J, Huang S, Yi Y, Bao S J Int Med Res. 2019; 47(5):2199-2206.

PMID: 30983484 PMC: 6567764. DOI: 10.1177/0300060519840890.

Alterations of COX-2, HER-2/neu and E-Cadherin protein expression in the prostatic adenocarcinoma: preliminary findings.

Musalam A, Andarawi M, Osman M, Al-Shriam M, Elrefaie A, Mahfouz A Am J Transl Res. 2019; 11(3):1653-1667.

PMID: 30972191 PMC: 6456505.

References

McPherson J, GOLDENBERG G . Induction of apoptosis by deregulated expression of DNA topoisomerase IIalpha. Cancer Res. 1998; 58(20):4519-24. View

Hortobagyi G . Treatment of breast cancer. N Engl J Med. 1998; 339(14):974-84. DOI: 10.1056/NEJM199810013391407. View

Rudolph P, MacGrogan G, Bonichon F, Frahm S, de Mascarel I, Trojani M . Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat. 1999; 55(1):61-71. DOI: 10.1023/a:1006159016703. View

Jarvinen T, Tanner M, Rantanen V, Barlund M, Borg A, Grenman S . Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol. 2000; 156(3):839-47. PMC: 1876829. DOI: 10.1016/s0002-9440(10)64952-8. View

Nakopoulou L, Lazaris A, Kavantzas N, Alexandrou P, Athanassiadou P, Keramopoulos A . DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer. Pathobiology. 2001; 68(3):137-43. DOI: 10.1159/000055914. View

Bakshi R, Galande S, Muniyappa K . Functional and regulatory characteristics of eukaryotic type II DNA topoisomerase. Crit Rev Biochem Mol Biol. 2001; 36(1):1-37. DOI: 10.1080/20014091074165. View

Coon J, Marcus E, Seelig S, Jacobson K, Chen S, Renta V . Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002; 8(4):1061-7. View

Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G . HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res. 2002; 8(5):1107-16. View

Eccles S . The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia. 2002; 6(4):393-406. DOI: 10.1023/a:1014730829872. View

10.

Wang J . Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002; 3(6):430-40. DOI: 10.1038/nrm831. View

11.

Park K, Kim J, Lim S, Han S . Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003; 39(5):631-4. DOI: 10.1016/s0959-8049(02)00745-1. View

12.

Akimitsu N, Adachi N, Hirai H, Hossain M, Hamamoto H, Kobayashi M . Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase IIalpha. Genes Cells. 2003; 8(4):393-402. DOI: 10.1046/j.1365-2443.2003.00643.x. View

13.

Akimitsu N, Kamura K, Tone S, Sakaguchi A, Kikuchi A, Hamamoto H . Induction of apoptosis by depletion of DNA topoisomerase IIalpha in mammalian cells. Biochem Biophys Res Commun. 2003; 307(2):301-7. DOI: 10.1016/s0006-291x(03)01169-0. View

14.

Jarvinen T, Liu E . HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer. Comb Chem High Throughput Screen. 2003; 6(5):455-70. DOI: 10.2174/138620703106298635. View

15.

Ross J, Fletcher J, Linette G, Stec J, Clark E, Ayers M . The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003; 8(4):307-25. DOI: 10.1634/theoncologist.8-4-307. View

16.

Sotiriou C, Neo S, McShane L, Korn E, Long P, Jazaeri A . Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003; 100(18):10393-8. PMC: 193572. DOI: 10.1073/pnas.1732912100. View

17.

Di Leo A, Isola J . Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?. Clin Breast Cancer. 2003; 4(3):179-86. View

18.

Cardoso F, Durbecq V, Larsimont D, Paesmans M, Leroy J, Rouas G . Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol. 2003; 24(1):201-9. View

19.

Petit T, Wilt M, Velten M, Millon R, Rodier J, Borel C . Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004; 40(2):205-11. DOI: 10.1016/s0959-8049(03)00675-0. View

20.

Durbecq V, Desmed C, Paesmans M, Cardoso F, Di Leo A, Mano M . Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int J Oncol. 2004; 25(5):1473-9. DOI: 10.3892/ijo.25.5.1473. View